Health
Calculate the HAS-BLED score to estimate major bleeding risk in patients on oral anticoagulation (most commonly combined with CHA₂DS₂-VASc in atrial fibrillation). Each component scores 1 point: Hypertension (uncontrolled, systolic BP >160), Abnormal renal function (dialysis/transplant/Cr >2.26 mg/dL), Abnormal liver function, prior Stroke, prior major Bleeding/predisposition, Labile INR (TTR <60% on warfarin), Elderly (age >65), Drugs (antiplatelet/NSAID), Alcohol (≥8 drinks/week). Range 0–9 (renal/liver and drugs/alcohol can each contribute up to 2). Interpretation: 0 low, 1–2 moderate, ≥3 high risk — regular review and correct reversible factors; a high score alone does NOT justify withholding anticoagulation. Derived from Pisters 2010 (Chest) and the 2023 ACC/AHA/ACCP/HRS AF guideline. The 'labile INR' criterion mainly applies to warfarin users; predictive value is lower for DOACs. Not medical advice.
Call this tool from your code in three languages.
curl -X POST 'https://api.elysiatools.com/en/api/tools/has-bled-score' \
-H 'Content-Type: application/json' \
-d '{"hypertension":true,"renal":false,"liver":false,"stroke":false,"bleeding":false,"labileInr":true,"elderly":true,"drugs":true,"alcohol":false}'Send a POST request with your inputs as JSON. File parameters require a separate upload first.
POST https://api.elysiatools.com/en/api/tools/has-bled-score| Name | Type | Required | Description |
|---|---|---|---|
| hypertension | checkbox | No | Uncontrolled hypertension, systolic BP > 160 mmHg. +1. |
| renal | checkbox | No | Chronic dialysis, renal transplant, or serum Cr > 2.26 mg/dL (>200 µmol/L). +1. |
| liver | checkbox | No | Chronic hepatic disease, or bilirubin > 2× ULN with AST/ALT/ALP > 3× ULN. +1. |
| stroke | checkbox | No | Prior stroke history. +1. |
| bleeding | checkbox | No |
Add this tool to your Model Context Protocol server so AI agents can list and call it.
Add this block to your MCP client configuration:
{
"mcpServers": {
"elysiatools-has-bled-score": {
"name": "has-bled-score",
"description": "Calculate the HAS-BLED score to estimate major bleeding risk in patients on oral anticoagulation (most commonly combined with CHA₂DS₂-VASc in atrial fibrillation). Each component scores 1 point: Hypertension (uncontrolled, systolic BP >160), Abnormal renal function (dialysis/transplant/Cr >2.26 mg/dL), Abnormal liver function, prior Stroke, prior major Bleeding/predisposition, Labile INR (TTR <60% on warfarin), Elderly (age >65), Drugs (antiplatelet/NSAID), Alcohol (≥8 drinks/week). Range 0–9 (renal/liver and drugs/alcohol can each contribute up to 2). Interpretation: 0 low, 1–2 moderate, ≥3 high risk — regular review and correct reversible factors; a high score alone does NOT justify withholding anticoagulation. Derived from Pisters 2010 (Chest) and the 2023 ACC/AHA/ACCP/HRS AF guideline. The 'labile INR' criterion mainly applies to warfarin users; predictive value is lower for DOACs. Not medical advice.",
"baseUrl": "https://api.elysiatools.com/mcp/sse?toolId=has-bled-score",
"command": "",
"args": [],
"env": {},
"isActive": true,
"type": "sse"
}
}
}After connecting to the SSE endpoint, list the exposed tools:
{
"jsonrpc": "2.0",
"id": 1,
"method": "tools/list"
}Invoke the tool by its id, passing arguments built from its parameters:
{
"jsonrpc": "2.0",
"id": 2,
"method": "tools/call",
"params": {
"name": "has-bled-score",
"arguments": {
"hypertension": true,
"renal": false,
"liver": false,
"stroke": false,
"bleeding": false,
"labileInr": true,
"elderly": true,
"drugs": true,
"alcohol": false
}
}
}| Prior major bleeding or predisposition to bleeding. +1. |
| labileInr | checkbox | No | Unstable/high INRs or time-in-therapeutic-range < 60% on warfarin. +1. Mainly applies to warfarin users. |
| elderly | checkbox | No | Age > 65 years. +1. |
| drugs | checkbox | No | Concomitant antiplatelet agent or NSAID use. +1. |
| alcohol | checkbox | No | Excess alcohol intake (≥ 8 drinks/week). +1. |
JSON result
{
"key": {...},
"metadata": {
"key": "value"
},
"error": "Error message (optional)",
"message": "Notification message (optional)"
}Questions or issues? Contact [email protected]